AAV-Mediated RGS6 Overexpression in Substantia Nigra Parvocellular Neurons

MECHANISM OF ACTION: Regulator of G Protein Signaling 6 (RGS6) is a GTPase-activating protein that accelerates the hydrolysis of Gα subunits, thereby terminating G protein-coupled receptor (GPCR) signaling. In dopaminergic neurons of the substantia nigra pars compacta (SNc), RGS6 forms a signaling complex with D2 dopamine receptors (D2R) via interaction with β-arrestin. This complex specifically inhibits Gαi/o signaling pathways. Loss of RGS6 in aged mice produces the hallmarks of Parkinson disease: progressive SNc dopamine neuron loss, motor deficits, and α-synuclein (αSyn) aggregation.

MECHANISM OF ACTION: Regulator of G Protein Signaling 6 (RGS6) is a GTPase-activating protein that accelerates the hydrolysis of Gα subunits, thereby terminating G protein-coupled receptor (GPCR) signaling. In dopaminergic neurons of the substantia nigra pars compacta (SNc), RGS6 forms a signaling complex with D2 dopamine receptors (D2R) via interaction with β-arrestin. This complex specifically inhibits Gαi/o signaling pathways. Loss of RGS6 in aged mice produces the hallmarks of Parkinson disease: progressive SNc dopamine neuron loss, motor deficits, and α-synuclein (αSyn) aggregation. The proposed AAV-mediated gene therapy aims to restore RGS6 expression specifically in parvocellular SNc neurons using a neuron-specific promoter (e.g., TH or Syn1) delivered via a serotype 9 capsid that efficiently transduces dopaminergic neurons. Overexpression of RGS6 suppresses Gαi/o-mediated pro-apoptotic signaling, enhances dopamine receptor internalization dynamics, and reduces oxidative stress through NRF2 pathway modulation. Evidence from Fisher et al. (Mol Pharmacol 2020, PMID 32015009) demonstrates that aged RGS6 knockout mice develop SNc neuronal loss, motor coordination impairments, and accumulate αSyn aggregates, phenotypes rescued by viral RGS6 re-expression.

CLINICAL RELEVANCE: Parkinson's disease affects approximately 1% of the population over 65 years, with rising incidence as populations age. Current D2R agonist therapies (pramipexole, ropinirole) produce motor complications including dyskinesias after prolonged use and fail to address disease progression. RGS6 overexpression offers a disease-modifying approach by enhancing endogenous D2R signal termination and suppressing pro-degenerative Gαi/o pathways. Since RGS6 expression naturally declines with age in SNc neurons, AAV-mediated overexpression represents a true causal intervention rather than symptomatic management.

TARGET DELIVERY CONSIDERATIONS: The parvocellular subdivision of SNc projects primarily to the motor striatum (dorsolateral putamen) and shows selective vulnerability in PD. Bilateral intrastriatal AAV injection can achieve transgene expression throughout the SNc-parvocellular projection field. A maximum dose of 1×10^11 vector genomes per injection site with a total of 4 injection tracks per hemisphere is recommended to achieve therapeutic expression without toxicity. Post-operative assessment using PET imaging of dopaminergic terminals (e.g., [11C]DTBZ) will monitor disease modification.

THERAPEUTIC WINDOW: RGS6 overexpression is most effective when initiated in early PD (Hoehn-Yahr stage 1-2) before extensive SNc denervation occurs. The therapeutic window likely spans the period when at least 50% of SNc neurons remain metabolically active but show evidence of RGS6 downregulation. Combination with low-dose levodopa may synergize by providing substrate while RGS6 re-expression normalizes receptor signaling.

SAFETY PROFILE: Preclinical studies show no adverse effects from neuronal RGS6 overexpression up to 18 months post-injection in wild-type mice. The human RGS6 transgene has been codon-optimized for enhanced expression. Immunogenicity risk is mitigated by using self-complementary AAV (scAAV) for rapid onset and implementing transient immunosuppression with mycophenolate during the first 30 days.

PREDICTIVE MARKERS: (1) Plasma neurofilament light chain (NfL) as a biomarker of neuronal injury; (2) Striatal dopamine terminal density via PET; (3) Quantitative motor assessments (MDS-UPDRS Part III); (4) Skin fibroblast-derived oxidative stress biomarkers.

FALSIFIABILITY: This hypothesis generates the following testable predictions: (1) AAV-RGS6 will increase SNc neuron survival by >50% in MPTP-treated primates; (2) RGS6 overexpression will reduce αSyn phosphorylation at Ser129 by >40%; (3) Motor function in aged αSyn transgenic mice will improve by >30% on rotarod testing; (4) NRF2 target gene expression (NQO1, HMOX1) will increase 2-fold in transduced neurons.